UK MHRA authorises BridgeBio's acoramidis for ATTR-CM
Acoramidis is an orally administered selective small molecule that stabilises transthyretin (TTR) by more than 90%.
This authorisation was supported by the outcomes from the pivotal ATTRibute-CM Phase III trial, which demonstrated cardiovascular benefits.
In the trial, the therapy's safety and efficacy were assessed in 632 symptomatic ATTR-CM subjects, and they were given either the therapy or a placebo for a 30-month period.
The primary clinical endpoints were met at month 30, showing a decrease in cardiovascular-related hospitalisations, preservation of functional capacity, improved survival and quality of life for subjects.
The therapy received the US Food and Drug Administration's (FDA) approval under the name Attruby in November 2024, and as Beyonttra by the European Commission (EC) in February 2025.
It was also approved in Japan by the Ministry of Health, Labour, and Welfare in March 2025.
In the UK, Bayer will manage all commercial activities for the therapy.
In March 2024, the company and Bayer entered a partnership granting the latter exclusive rights to commercialise the therapy in Europe.
According to the licencing agreement, BridgeBio will obtain tiered royalties starting in the low-thirties percent on UK sales after commercialisation efforts commence.
ATTR-CM is a fatal condition that causes heart failure due to restrictive cardiomyopathy.
BridgeBio Cardiorenal chief medical officer and president Jonathan Fox stated: 'We are proud to add another approval for acoramidis and thrilled that patients in the UK will now have access to Beyonttra since they are in great need of new disease-modifying treatments for their condition.
'We look forward to extending our collaboration with our European partner, Bayer, to serve ATTR-CM patients across the UK and the rest of Europe, and will continue to work towards reaching patients in as many regions as possible around the world."
"UK MHRA authorises BridgeBio's acoramidis for ATTR-CM" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
a day ago
- Miami Herald
Bayer reaches deal over Seattle-area school PCB cases
Bayer AG agreed to settle cases related to a Seattle-area school where more than 200 people were exposed to toxic chemicals made by the company's Monsanto unit. Bayer didn't disclose the financial terms of the accord, but said the cost was covered by a $618.1 million provision taken this month to deal with the company's liabilities for polychlorinated biphenyls, or PCBs, once manufactured by Monsanto. The company's shares rose 2.3% in Germany. Ex-students and teachers at the Sky Valley School outside Seattle sued Bayer and Monsanto over injuries tied to PCBs contained in aging fluorescent-light fixtures. The deal announced by Bayer - already enmeshed in multiyear litigation over its herbicide Roundup - is seen as a positive development in its handling of a wave of PCB lawsuits over Monsanto building materials made half a century ago. "This development suggests progress toward containing PCB liabilities and reducing the risk of swelling," analysts at Jefferies wrote in a note. Bayer, which acquired Monsanto in 2018 for $63 billion, already has agreed to pay almost $2 billion in settlements in PCB cases brought by states, cities and counties. Separate litigation over Monsanto's Roundup weedkiller has created a drag on the German conglomerate's shares. The company has reserved more than $17 billion for U.S. Roundup suits. Monsanto stopped using PCBs in its products in 1977. Analysts have cast a wary eye on Bayer's burgeoning PCB problem. Bloomberg Intelligence analyst Holly Froum has projected it may cost Monsanto and two other companies embroiled in PCBs litigation - Eastman Chemical's Solutia and Pfizer's Pharmacia - as much as $3.9 billion to settle the remaining cases. The settlement announced Monday covers more than 200 plaintiffs with ties to the Sky Valley School, Bayer said. It doesn't wipe out the 10 verdicts in which juries in Washington State already have awarded a total of more than $1 billion, the company said. Those awards are under appeal. Bayer is asking the Washington Supreme Court to throw out the PCB verdicts based on its legal defenses. The court heard arguments in February, but has yet to hand down a ruling. An intermediate appellate court's backing of Bayer's position on the PCB cases prompted the review by the state's highest court. "While the company remains confident in its legal strategy and defenses, and is fully prepared to defend cases at trial, it has maintained it will consider resolving cases on appropriate terms when it is strategically advantageous to help mitigate the risks and uncertainties of this litigation," Bayer officials said in a release. Washington verdict Earlier this year, state-court jurors in Washington ordered Bayer to pay $100 million to students and teachers exposed to PCBs, which were used used in electrical transformers, paints and sealants for their fire-resistant properties. The compounds were banned in the U.S. in 1979 after researchers found they posed a cancer risk. The company still faces dozens of PCB suits by school districts, states and cities over health exposure and environmental contamination in buildings, landfills and waterways, according to Bayer's 2023 annual report. The case before the Washington Supreme Court is Erickson v. Pharmacia LLC, No. 103135-1, Washington Supreme Court (Olympia) (With assistance from Sonja Wind.) Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Fast Company
2 days ago
- Fast Company
How to truly change your organization
In March 2024, Bill Anderson, pharma giant Bayer's CEO, wrote an op-ed in Fortune vowing to bust bureaucracy, slash red tape, and eliminate layers of middle management to create a more agile and innovative enterprise. 'Our radical reinvention will liberate our people while cutting 2 billion euros in annual costs by 2026,' he wrote. I wrote soon after that what Anderson was doing wasn't genuine transformation but had all the telltale signs of transformation theater: a false sense of urgency calling for drastic action when none is needed, a rushed strategic process (with little or no time for analysis or dissent), and a large, premature public rollout. Today, more than a year later, Bayer's stock remains near all-time lows and investors are increasingly frustrated and it's not hard to see why. Anderson went into an organization that was already reeling and introduced even more stress and disruption, with predictable results. If you want to create genuine transformation, you need to start by creating a sense of safety. The Disruption Mindset By publishing his manifesto in Fortune just nine months into his tenure, Anderson was following the advice of many change gurus: create urgency. Burn the boats. Announce the plan loudly and publicly so there's no turning back. That's the disruption mindset. But was that really necessary—or even helpful? The problems that Bayer faced had been building for years. Its 2018 acquisition of Monsanto made it liable for billions of dollars of lawsuits related to the herbicide Roundup, which is thought to cause cancer. The firm had been building up debt for years and it had long been clear that patents of blockbuster drugs, such as Xarelto, were set to expire. None of this was a secret to anyone. As Anderson himself noted, the stock price had fallen by half during his tenure and was at a 20-year low. It's also not clear how a reorganization would address those problems. Litigation and debt don't immediately disappear just because you eliminate middle managers, nor does it help discover new drugs to replace expiring patents. Consider what the last few years have been like for a typical Bayer employee. First came a massive restructuring after the Monsanto deal. Then came years of public headlines about lawsuits, debt, and falling performance. And now, a new CEO storms in and announces he's eliminating thousands of jobs and redesigning every role and process in the company. Would that make you feel 'liberated,' as Anderson put it? Or terrified? The Truth About Disruption And Performance A key rationale underlying the disruption mindset is that it promotes creativity and innovation. Undermining the status quo, the logic goes, creates space for the new and different. Yet there is little evidence that this is an effective approach and much that suggests a disruptive environment impairs creativity and innovation. In Cultures of Growth, Stanford social psychologist Mary C. Murphy points out that disruption impedes the growth mindset that is so necessary for supporting an innovative culture. In particular, she cites Amy Edmondson's research on psychological safety, which indicates that fear inhibits learning. She also points to laboratory experiments that suggest that performance goals impede working memory, a key component of creative thinking. One thing that you begin to notice when you spend a lot of time around people who perform at a world-class level is that they are more prone to anxiety. So when you shake things up, you're most likely to rattle the very people you can least afford to lose and who can most easily leave. Bayer's business is, on a certain level, fairly simple: As long as it produces a steady stream of breakthrough discoveries, things will go well. But once that dries up, it becomes very tough to make money. Sustaining that flow means attracting and motivating exactly the kind of smart, ambitious people who are most vulnerable to—and least tolerant of—disruptive management. Stability Fuels Innovation My friend Whitney Johnson has argued passionately for the need to disrupt ourselves. It is only through venturing out of our comfort zones that we can explore new things, gain new skills, and push our boundaries. That's what makes the difference between mediocre also-rans and truly top performers. Yet when we had Whitney on the Changemaker Mindset podcast, I noticed something interesting. Whenever she reached a juncture where she needed to disrupt herself, she always mentioned her husband. As we discussed the pattern further, it soon became clear that it was the love and support from her husband that provided the safety and stability she needed to continually disrupt herself. Whitney's not alone. We all need a sense of safety if we are going to take risks. That's why, when IBM was on the verge of collapse, Lou Gerstner made sure his first trip was to IBM's famed Thomas Watson Research Center, not to demand results, but to reassure the scientists that he was committed to supporting their work. When Alcoa was at a similar point, its new CEO, Paul O'Neill, made his commitment to safety, not profits. Many would say that all sounds nice, but naive. The real world is hard-nosed and cutthroat. Yet both Gerstner and O'Neill were seasoned leaders, not wide-eyed idealists, and both took failing companies and transformed them into record-setting profitability in a short time. They did it not by disrupting their organizations, but by making them feel safe enough to embrace change. Creating Safety In 1997, when Clayton Christensen first published The Innovator's Dilemma and introduced the term 'disruptive innovation,' it was a clarion call. His key insight was that, under certain conditions, the basis of competition in an industry shifts, and the strategies that once made incumbents successful can suddenly make them vulnerable. Yet what Christensen didn't anticipate was how seductive the idea of disruption would become. Soon, all manner of pundits—most of whom never read his book or understood his concepts—were preaching the gospel of disruption. Before you knew it, everything had to be disrupted all the time. But the truth was, we weren't disrupting industries, but disrupting people. The unfortunate reality is that when most leaders talk about disruption, they're not thinking about business strategy but elevating themselves. Disruption becomes a personal brand. A way to feel bold, daring, and visionary. Yet while they are glorifying themselves, they're making things harder for everyone else and there's a cost to that. Genuinely visionary leaders know that disruption and safety go hand in hand. The safer you make your organization, the more you empower your people to think boldly, take risks, and explore new territory. The more stress you create, the more you drain cognitive capacity, limit creativity and shrink the space people have for insight, collaboration, and original thinking.
Business Wire
5 days ago
- Business Wire
Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer's Aspirina, the #1 pain relief option in Mexico 1, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. With a deep commitment to Hispanic consumers, Aspirina is poised to provide an accessible and effective solution for pain relief. Bayer's Aspirina, the #1 pain relief option in Mexico, is now available for purchase in the United States, bringing a well-known brand to the Hispanic community. Share As the Hispanic population in the U.S. continues to grow, currently representing 19 percent of the population and projected to reach 28 percent by 2060, Bayer Aspirin recognizes the importance of connecting with this vibrant community. The Aspirina pain relief option resonates deeply with cultural values and family traditions of those from Mexican and Latin American descent who have been using it as a long-standing pain relief option. 'Many Hispanic communities still face inadequate access to healthcare and consumer goods. As the fastest-growing demographic group in the U.S., the Hispanic population presents a unique opportunity for Bayer. By adding Aspirina to the U.S. portfolio, which has a strong equity in LATAM, we are placing the consumer at the center of our strategy. Data shows that 70 percent of Hispanic consumers feel a strong connection to their country of origin, making it essential for brands to honor and reflect this sentiment,' said Mohamed Atef, Global Brand Lead for Aspirin at Bayer. Many U.S. consumers of Hispanic origin grew up with Bayer's Aspirina— their parents and grandparents relied on it, instilling trust and nostalgia for the brand. Due to those deep connections, Aspirina has a 99 percent awareness rate in Mexico, with 67 percent of consumers using it regularly 2. With this inclusion in the U.S. market, we invite consumers to reconnect with a product that represents reliability, familiarity and their heritage. Bayer invented modern aspirin 125 years ago, and it's the most trusted aspirin brand for pain relief in the U.S. 3 Many pain reliever brands have come and gone over the last century, but Bayer® Aspirin continues to be one of the most trusted pain brands on the market. Aspirina is available at select Walmart and Walgreens, making it easy for families to find the pain relief they know. Join us in celebrating the launch of Aspirina in the U.S. and rediscover a brand that feels like home — a trusted companion in the journey of life. For more information on Aspirina visit About Aspirina For over 125 years, Bayer® Aspirin has been a leading aspirin brand in proven pain relief. Aspirina is a powerful pain reliever and fever reducer that contains 500 mg of the active ingredient aspirin (NSAID*). It provides fast and effective multi-symptom relief of headaches, muscle pain, toothaches, menstrual pain and minor arthritis pain for adults and children over 12, when used as directed. Aspirina is coated to make it easy to swallow and is free of caffeine. *nonsteroidal anti-inflammatory drug About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 1 Based on volume sales in the last 52 weeks, via source: Grupo Knoblock/CID – Centro Integrador de Datos
